Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Immuno-Oncology Congress 2023

Is TMB a good predictive biomarker for immunotherapy?

Second vote and conclusions

Date

07 Dec 2023

Session

Is TMB a good predictive biomarker for immunotherapy?

Topics

Therapy

Tumour Site

Presenters

Aurelien Marabelle

Authors

A. Marabelle

Author affiliations

  • Institut Gustave Roussy, 94805 - Villejuif/FR

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Introduction and first vote

Presenter: Aurelien Marabelle

Session: Is TMB a good predictive biomarker for immunotherapy?

Resources:

Slides

Webcast

Yes

Presenter: Francois Ghiringhelli

Session: Is TMB a good predictive biomarker for immunotherapy?

Resources:

Slides

Webcast

No

Presenter: Benoit Rousseau

Session: Is TMB a good predictive biomarker for immunotherapy?

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.